PERMANENT DAMAGE TO THE NERVOUS SYSTEM FOLLOWING AN ATTACK OF POLYRADICULONEURITIS (GUILLAIN-BARRÉ SYNDROME)

Guillain-Barré syndrome (GBS) is an acute demyelinating disorder of the peripheral nervous system that results in motor weakness, absent reflexes and autonomic nervous system dysfunction. Autonomic failure is reported in approximately 65 % of patientswith GBS and usually follows extensive motor involvement. In this case our patient presented with syncope and other signs of autonomic failure before the motor weakness developed. Few cases in the literature have reported features of autonomic failure before established weakness in GBS; to our knowledge, syncope has not been described previously as a presenting feature of GBS.

Download Full-text

The Development of Guillain Barre Syndrome Subsequent to Administration of Ad26.COV2.S Vaccine

10.47363/jnrrr/2021(3)140 ◽

2021 ◽

pp. 1-3

Author(s):

Rachel Koreen ◽

◽

Jacob Chevlen DO ◽

Keyword(s):

Nervous System ◽

Respiratory Failure ◽

Molecular Mimicry ◽

Asymptomatic Infection ◽

Guillain Barre Syndrome ◽

Neurologic Disorder ◽

Diagnostic Certainty ◽

Guillain Barré Syndrome ◽

Level 3 ◽

Guillain Barré

Guillain Barre Syndrome (GBS) is a rare neurologic disorder in which the immune system mistakenly attacks the peripheral nervous system due to molecular mimicry. GBS symptoms can range from a mild episode of weakness to devastating paralysis and respiratory failure. The exact cause of GBS is unknown, but it is often thought to be due to a preceding viral infection or rarely due to vaccination. To date, there has only been one reported case of Guillain Barre Syndrome associated with the administration of Ad26.COV2.S vaccine (Janssen/Johnson & Johnson COVID-19 vaccine) [3]. Here, we describe the case of a 59-year-old woman who received the Johnson & Johnson COVID-19 vaccine and subsequently developed symptoms consistent with GBS. Unfortunately, due to failure to obtain lumbar puncture (LP) and electromyography (EMG), it is only possible to diagnose Guillain Barre syndrome with Level 3 diagnostic certainty using the Brighton criteria [6]. We are of the opinion that our patient developed GBS subsequent to the vaccination, but not necessarily consequent to the vaccination, as it remains possible that she may have contracted an asymptomatic infection prior to inoculation

Download Full-text

Guillain-Barre Syndrome Caused by Tislelizumab and Axitinib

10.21203/rs.3.rs-564774/v1 ◽

2021 ◽

Author(s):

Yang Sun ◽

Yanjun Guo ◽

Yaqing Wu ◽

Ningning Luo ◽

Xinjia He

Keyword(s):

Renal Cell Carcinoma ◽

Nervous System ◽

T Cell ◽

Adverse Events ◽

Renal Cell ◽

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Treatment Paradigm ◽

Triggering Factor ◽

Guillain Barré

Abstract Immunotherapy combinations have changed the treatment paradigm of advanced renal cell carcinoma (RCC). Notably, immunotherapy induces a new spectrum of immune-related adverse events (irAEs). Guillain–Barré syndrome (GBS) is a rare and potentially fatal nervous system irAE. The activation of T-cell is considered a triggering factor of GBS. We herein reported a case of GBS-like syndrome during treatment of tislelizumab and axitinib in a patient with RCC. To our knowledge, this is the first report of tislelizumab-related GBS.

Download Full-text

Central nervous system demyelination complicating Guillain-Barré syndrome

Neuropediatrics ◽

10.1055/s-0033-1337709 ◽

2013 ◽

Vol 44 (02) ◽

Author(s):

M Häusler ◽

K Claeys ◽

M Schoberer ◽

V Busch ◽

K Rostásy ◽

...

Keyword(s):

Central Nervous System ◽

Nervous System ◽

Guillain Barre Syndrome ◽

Guillain Barré Syndrome ◽

Central Nervous System Demyelination ◽

Guillain Barré

Download Full-text

Guillainbarré Syndrome not responding to Remdesivir, Enoxaparin and High dose methylprednisolone in Patient with Covid 19 and eclampsia in Pregnancy: A case report.

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11ispl1.4291 ◽

2020 ◽

Vol 11 (SPL1) ◽

pp. 1815-1818

Author(s):

Dibya Jyoti Sharma ◽

Aveenash Pawar ◽

Phulen Sarma ◽

Gaurav Muktesh

Keyword(s):

Nervous System ◽

Case Report ◽

Post Partum ◽

The Body ◽

Guillain Barre Syndrome ◽

High Dose ◽

Standard Medical Therapy ◽

High Dose Methylprednisolone ◽

Guillain Barré Syndrome ◽

Guillain Barré

COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has protean manifestations. Nervous system involvement though uncommon in COVID-19 can present with debilitating manifestations like necrotising encephalopathy, myopathy, seizure, peripheral neuropathy and Guillain Barré syndrome. In this case report, we report a case of 27 years old woman who presented to us with post partum eclampsia and developed acute flaccid quadriparesis 5 days after COVID-19 infection which was manifested as cough, anosmia and ageusia without fever. Patient developed dyspnoea followed by type 2 respiratory failure 8 days after hospitalization for which she was put into mechanical ventilation. She was treated with high dose Methylprednisolone and standard medical therapy. IVIG or plasmapheresis could not be given due to non-availability. Patient expired in ICU after 18 days of hospital admission. SARS-COV-2 mainly infects the respiratory system of the body but it may have the neurotropic capacity and its ability to produce immune dysregulation can produce a cascade of inflammatory reactions in the nervous system. Guillain Barré syndrome is a heterogeneous disorder triggered by many viral infections and its development following COVID-19 infection can be attributed to the virus or immune response of the host against it. Possibility of COVID-19 infection triggering Guillain Barré syndrome cannot be ruled out. More studies regarding association of COVID-19 with the neurological disease may help in unraveling the neuro-invasion ability of the virus and to develop measures to prevent it.

Download Full-text